📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: MacroGenics

1.1 - Company Overview

MacroGenics Logo

MacroGenics

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of immunotherapeutics, including antibody-drug conjugates and DART bispecifics targeting B7-H3, PD-1×CTLA-4 and CD123, to treat metastatic castration-resistant prostate cancer, advanced solid tumors, CD123-positive neoplasms (AML, MDS) and multiple cancers; programs include vobramitamab duocarmazine, lorigerlimab, MGD024, MGC026, MGC028 and enoblituzumab.

Products and services

  • Lorigerlimab: A tetravalent PD-1 × CTLA-4 DART molecule developed to treat metastatic castration-resistant prostate cancer in combination with docetaxel
  • Vobramitamab Duocarmazine (vobra duo): A B7-H3-targeted antibody-drug conjugate engineered for treating metastatic castration-resistant prostate cancer, with plans for application across additional cancers
  • MGD024: A DART-based CD123 × CD3 molecule created to treat CD123-positive neoplasms, including acute myeloid leukemia and myelodysplastic syndromes

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to MacroGenics

Inviragen Logo

Inviragen

HQ: United States Website
  • Description: Provider of life-saving vaccines in development to protect against emerging infectious diseases worldwide, including a lead dengue fever vaccine and a West Nile virus vaccine for North America.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Inviragen company profile →
TG Therapeutics Logo

TG Therapeutics

HQ: United States Website
  • Description: Provider of biopharmaceutical therapies for hematologic malignancies and autoimmune disorders, including BRIUMVI, a treatment for relapsing forms of multiple sclerosis—clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease—in adults.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full TG Therapeutics company profile →
CellPoint Logo

CellPoint

HQ: The Netherlands Website
  • Description: Provider of point-of-care CAR-T therapy solutions enabling clinicians to retarget patient immune cells to treat hematological malignancies, with a 6-day manufacturing process powered by the proprietary xCellit real-time monitoring software system that allows for 1 week vein-to-vein time, making therapies more affordable and accessible.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full CellPoint company profile →
Immunovant Logo

Immunovant

HQ: United States Website
  • Description: Provider of clinical-stage biopharmaceutical offerings focused on enabling normal lives for patients with autoimmune diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Immunovant company profile →
Avaxia Biologics Logo

Avaxia Biologics

HQ: United States Website
  • Description: Provider of orally delivered, gut-targeted antibody therapeutics using a proprietary platform, including Avaximab-TNF for local intestinal anti-TNF action in inflammatory bowel disease; AVX-470, an oral anti-TNF polyclonal antibody from bovine milk evaluated in Phase 1b for ulcerative colitis; and the Avaximabs platform for recombinant antibodies that withstand the GI environment and act locally.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Avaxia Biologics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for MacroGenics

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to MacroGenics

2.2 - Growth funds investing in similar companies to MacroGenics

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for MacroGenics

4.2 - Public trading comparable groups for MacroGenics

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to MacroGenics

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About MacroGenics

What does MacroGenics do?

MacroGenics is a provider of immunotherapeutics, including antibody-drug conjugates and DART bispecifics targeting B7-H3, PD-1×CTLA-4 and CD123, to treat metastatic castration-resistant prostate cancer, advanced solid tumors, CD123-positive neoplasms (AML, MDS) and multiple cancers; programs include vobramitamab duocarmazine, lorigerlimab, MGD024, MGC026, MGC028 and enoblituzumab.

Who are MacroGenics's competitors?

MacroGenics's competitors and similar companies include Inviragen, TG Therapeutics, CellPoint, Immunovant, and Avaxia Biologics.

Where is MacroGenics headquartered?

MacroGenics is headquartered in United States.

How many employees does MacroGenics have?

MacroGenics has 1,000 employees 🔒.

When was MacroGenics founded?

MacroGenics was founded in 2010 🔒.

What sector and industry vertical is MacroGenics in?

MacroGenics is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for MacroGenics

Who are the top strategic acquirers in MacroGenics's sector and industry

Top strategic M&A buyers and acquirers in MacroGenics's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for MacroGenics?

Top strategic M&A buyers groups and sectors for MacroGenics include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in MacroGenics's sector and industry vertical

Which are the top PE firms investing in MacroGenics's sector and industry vertical?

Top PE firms investing in MacroGenics's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in MacroGenics's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in MacroGenics's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in MacroGenics's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to MacroGenics include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in MacroGenics's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for MacroGenics?

The key public trading comparables and valuation benchmarks for MacroGenics include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for MacroGenics for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for MacroGenics with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in MacroGenics's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for MacroGenics with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in MacroGenics's' sector and industry vertical?

Access recent funding rounds and capital raises in MacroGenics's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for MacroGenics